Stockscreener 앱 받기
2.71
1.09%
-0.03
시간 외 거래:
2.69
-0.02
-0.74%
전일 마감가:
$2.74
열려 있는:
$2.74
하루 거래량:
1.73M
Relative Volume:
0.78
시가총액:
$543.00M
수익:
$216.56M
순이익/손실:
$-9.57M
주가수익비율:
-54.53
EPS:
-0.0497
순현금흐름:
$-1.22M
1주 성능:
+15.81%
1개월 성능:
+39.69%
6개월 성능:
+67.28%
1년 성능:
+116.80%
1일 변동 폭
$2.69
$2.81
1주일 범위
$2.34
$2.87
52주 변동 폭
$1.15
$3.15
Cerus Corp Stock (CERS) Company Profile
명칭
Cerus Corp
전화
(925) 288-6000
주소
1220 CONCORD AVENUE, CONCORD, CA
Compare CERS vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CERS
Cerus Corp
|
2.71 | 549.01M | 216.56M | -9.57M | -1.22M | -0.0497 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cerus Corp Stock (CERS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-12 | 개시 | Craig Hallum | Buy |
| 2023-01-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-06-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-02-26 | 개시 | BTIG Research | Buy |
| 2019-11-13 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-08-28 | 개시 | Stifel | Buy |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2018-01-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2017-12-08 | 재개 | BTIG Research | Neutral |
| 2016-07-07 | 재개 | Cantor Fitzgerald | Buy |
| 2015-12-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2014-05-02 | 재확인 | MLV & Co | Buy |
| 2013-04-24 | 재확인 | Cantor Fitzgerald | Buy |
| 2013-03-15 | 재확인 | MLV & Co | Buy |
| 2012-04-17 | 개시 | Cantor Fitzgerald | Buy |
| 2012-02-29 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2011-11-10 | 재확인 | MLV & Co | Buy |
| 2011-06-03 | 개시 | Wedbush | Outperform |
| 2011-03-04 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2010-03-09 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2009-08-26 | 업그레이드 | Avondale | Mkt Perform → Mkt Outperform |
모두보기
Cerus Corp 주식(CERS)의 최신 뉴스
What’s Fueling New Momentum Across Penny Stock Markets? - Kalkine Media
Q1 2026 Cerus Corp Earnings Call Transcript - GuruFocus
Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG - Insider Monkey
Cerus Corporation (CERS) Q1 2026 Earnings: EPS Surprises to the Upside as Loss NarrowsCrowd Breakout Signals - Newser
Cerus Corp stock (US1570851014): turnaround hopes after sharp rally in blood safety specialist - AD HOC NEWS
Are NYSE Penny Stocks Showing Mixed Financial Strength? - Kalkine Media
Cerus Corp stock (US1570851014): blood safety specialist in focus after Q1 2026 update - AD HOC NEWS
Cerus Corp stock (US1570851014): blood safety specialist back in focus after latest business update - AD HOC NEWS
Cerus Corp stock (US1570851014): Recent 2.21% gain amid mixed signals - AD HOC NEWS
Cerus Is Finding Its Next Gear In Blood Safety - Finimize
Vivek Jayaraman Sells 16,667 Shares of Cerus (NASDAQ:CERS) Stock - MarketBeat
Cerus corp COO Vivek Jayaraman sells $50,001 in common stock By Investing.com - Investing.com Australia
Cerus corp COO Vivek Jayaraman sells $50,001 in common stock - Investing.com
Cerus (CERS) COO sells 16,667 shares in planned 10b5-1 trade - Stock Titan
Cerus Momentum Builds Amid Healthcare Innovation Buzz On Nasdaq Composite - Kalkine Media
Cerus (NASDAQ:CERS) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
Cerus Company Profile & Introduction - Moomoo
Cerus (NASDAQ:CERS) Upgraded by Zacks Research to Hold Rating - MarketBeat
Cerus Corporation Reports First Quarter 2026 Financial Results - HarianBasis.co
Cerus (NASDAQ:CERS) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Cerus Corporation Q1 2026 SEC Filing: Financial Statements, Risk Factors, and Management Discussion - Minichart
[144] CERUS CORP SEC Filing - Stock Titan
Insider sale filings: CERS (NASDAQ: CERS) reports restricted stock dispositions - Stock Titan
CERS Upgraded by BTIG -- Price Target Announced at $4.00 - GuruFocus
Cerus (NASDAQ:CERS) Reaches New 12-Month High After Better-Than-Expected Earnings - MarketBeat
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
CERSCerus Corp Stock Price and Quote - Finviz
BTIG Research Upgrades Cerus (NASDAQ:CERS) to "Buy" - MarketBeat
Cerus Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Cerus Corporation (NASDAQ:CERS) Q1 2026 Earnings Call Transcript - Insider Monkey
Cerus Corp (CERS) Q1 2026 Earnings Call Highlights: Strong Reven - GuruFocus
Cerus (NASDAQ:CERS) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Is Cerus (CERS) 8.6% Undervalued After Q1 2026 Earnings Beat? EP - GuruFocus
Cerus Q1 Earnings Call Highlights - MarketBeat
Cerus (NASDAQ: CERS) grows Q1 2026 revenue and sharply cuts net loss - Stock Titan
Cerus Q1 2026 Earnings Call Transcript - Benzinga
Earnings call transcript: Cerus Corporation Q1 2026 beats EPS forecast - Investing.com
Cerus Corp 1Q 2026: Revenue $59.9M, EPS $(0.01) — 10-Q Summary - TradingView
Cerus Corporation (CERS) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Cerus Corp (NASDAQ:CERS) Surges on Strong Q1 Beat and Raised Guidance - ChartMill
Cerus: Q1 Earnings Snapshot - San Francisco Chronicle
Cerus Reports Q1 2026 Revenue $59.9M, Product Revenue Up 24% and Raises 2026 Product Guidance - TradingView
Cerus Corporation (NASDAQ: CERS) lifts 2026 outlook after strong Q1 results - Stock Titan
Blood safety company Cerus lifts 2026 forecast after 24% product-sales jump - Stock Titan
Cerus signs four-year supply deal with French blood service - Investing.com
Cerus signs four-year supply deal with French blood service By Investing.com - Investing.com Canada
Cerus wins 4-year deal with French blood network serving 330,000 units - Stock Titan
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System - Yahoo Finance
CERS SEC FilingsCerus 10-K, 10-Q, 8-K Forms - Stock Titan
Cerus (CERS) to Release Earnings on Thursday - MarketBeat
[ARS] CERUS CORP SEC Filing - Stock Titan
Cerus Corp (CERS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.22%
1.41%
자본화:
|
볼륨(24시간):